Search Results | MSF Science Portal

Journal Article

|

Research

Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Abubakirov A, et al.

2025-01-29 • New England Journal of Medicine

BACKGROUND

For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs ...

Journal Article

|

Research

Khan U, Rich M, Franke M, Lachenal N, Ahmed S, et al.

2024-12-10 • Clinical Infectious Diseases

BACKGROUND

The 2022 WHO guidelines on multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) recommend six months of bedaquiline (Bdq) in the all-oral 9-month shorter regimen ...

Conference Material

|

Slide Presentation

Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Lachenal N, et al.

2024-05-16 • MSF Scientific Day International 2024

Conference Material

|

Abstract

Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Lachenal N, et al.

2024-05-16 • MSF Scientific Day International 2024

INTRODUCTION
Tuberculosis (TB) is a major public health challenge encountered across many Médecins Sans Frontières (MSF) fields. Management of drug-resistant TB is an operational pri...

Journal Article

|

Research

Kho S, Seung KJ, Huerga H, Bastard M, Khan PY, et al.

2024-05-09 • Nature Communications

Sputum culture reversion after conversion is an indicator of tuberculosis (TB) treatment failure. We analyze data from the endTB multi-country prospective observational cohort (NCT032592...

Journal Article

|

Research

Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Abubakirov A, et al.

2024-01-29 • medRxiv

BACKGROUND

Aft...

Journal Article

|

Research

Zeng C, Hernán MA, Trevisi L, Sauer S, Mitnick CD, et al.

2024-01-20 • medRxiv

RATIONALE

Treatment outcomes may be compromised among patients with multidrug- or rifampicin-resistant tuberculosis with additional fluoroquinolone resis...

Journal Article

|

Research

Rodriguez CA, Lodi S, Horsburgh CR, Bastard M, Hewison C, et al.

2022-11-10 • PLOS One

BACKGROUND

Journal Article

|

Research

Seung KJ, Khan P, Franke MF, Ahmed S, Aiylchiev S, et al.

2020-07-11 • Clinical Infectious Diseases

Delamanid should be effective against highly resistant strains of Mycobacteriumtuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observati...

Journal Article

|

Research

Franke MF, Khan P, Hewison C, Khan U, Huerga H, et al.

2021-01-01 • American Journal of Respiratory and Critical Care Medicine

RATIONALE
Bedaquiline and delamanid offer the possibility of more effective and less toxic treatment for multidrug-resistant (MDR) tuberculosis (TB). With this treatment, however, so...

Technical Report

|

Study report

Atwood S, Avagyan N, Bastard M, Cain M, Collin S, et al.

2018-07-01

Science Portal

Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis

The frequency and incidence of QT prolongation with extended use of bedaquiline or delamanid in a large, multi-country MDR/RR-TB cohort

Improving treatment of multidrug-resistant tuberculosis: Results of the endTB randomised clinical trial

Improving treatment of multidrug-resistant tuberculosis: Results of the endTB randomised clinical trial

Sputum culture reversion in longer treatments with bedaquiline, delamanid, and repurposed drugs for drug-resistant tuberculosis

Nine-month, all-oral regimens for rifampin-resistant tuberculosis

Effectiveness of a bedaquiline, linezolid, clofazimine “core” for multidrug-resistant tuberculosis

Selection bias in multidrug-resistant tuberculosis cohort studies assessing sputum culture conversion

BACKGROUND

Culture conversion at 6 months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis

Culture conversion in patients treated with bedaquiline and/or delamanid. A prospective multicountry study

endTB interim analysis report - Bedaquiline- and delaminid- containing regimens achieve excellent interim treatment response without safety concerns